Drug news

Ironwood Pharma to co-promote Viberzi (eluxadoline) in the US with Allergan for irritable bowel syndrome

Read time: 1 mins

Last updated:6th Aug 2015

Published:6th Aug 2015

Source: Pharmawand

Ironwood Pharmaceuticals announced an agreement with Allergan plc for the US co-promotion of Viberzi (eluxadoline), Allergan’s new treatment for adults suffering from irritable bowel syndrome with diarrhoea (IBS-D). This arrangement is separate from and complementary to the companies’ ongoing co-development and co-commercialisation of linaclotide (Linzess, or Constella in the EU) for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).

Comment; Viberzi was US approved in May 2015. Ironwood has a specialty sales force of about 25,000 reps who will now co-promote Viberzi alongside Allergan – Linzess will remain the lead product.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Safety of switching from a Vitamin K antagonist to a non–Vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation.

FRAIL-AF trial investigators set out to study the question of whether frail, elderly patients with atrial fibrillation who were doing well with vitamin K antagonists (VKA) should be switched to direct-acting oral anticoagulants (DOAC).

1 mins

Drug news

FDA approves updated Lupkynis (voclosporin) label to include long term data from the Aurora Clinical Program.-- Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals Inc. announced that the FDA has approved a label update for Lupkynis. The updated label no longer includes language indicating that the safety and efficacy of Lupkynis has not been established beyond one year.

3 min

Drug news

Phase III KEYNOTE-811 trial met dual primary endpoint of overall survival (OS) as first-line treatment in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.- Merck Inc.,

Merck Inc., known as MSD outside of the United States and Canada, announced that the Phase III KEYNOTE-811 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy met its dual primary endpoint of overall survival (OS) for the first-line treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

1 min

See all news